Abbott Laboratories (NYSE:ABT) Shares Purchased by Bath Savings Trust Co

Bath Savings Trust Co raised its holdings in shares of Abbott Laboratories (NYSE:ABTFree Report) by 2.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 155,835 shares of the healthcare product maker’s stock after purchasing an additional 3,549 shares during the quarter. Abbott Laboratories accounts for 1.9% of Bath Savings Trust Co’s portfolio, making the stock its 15th largest position. Bath Savings Trust Co’s holdings in Abbott Laboratories were worth $17,153,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the business. Capital Asset Advisory Services LLC grew its stake in Abbott Laboratories by 10.5% during the 4th quarter. Capital Asset Advisory Services LLC now owns 22,246 shares of the healthcare product maker’s stock valued at $2,449,000 after purchasing an additional 2,108 shares in the last quarter. Southland Equity Partners LLC lifted its holdings in Abbott Laboratories by 2.5% during the 4th quarter. Southland Equity Partners LLC now owns 4,912 shares of the healthcare product maker’s stock worth $541,000 after buying an additional 119 shares during the last quarter. Farmers Trust Co. lifted its holdings in Abbott Laboratories by 3.8% during the 4th quarter. Farmers Trust Co. now owns 24,746 shares of the healthcare product maker’s stock worth $2,724,000 after buying an additional 909 shares during the last quarter. Beese Fulmer Investment Management Inc. lifted its holdings in Abbott Laboratories by 0.4% during the 4th quarter. Beese Fulmer Investment Management Inc. now owns 94,394 shares of the healthcare product maker’s stock worth $10,390,000 after buying an additional 414 shares during the last quarter. Finally, Wedmont Private Capital lifted its holdings in Abbott Laboratories by 25.5% during the 4th quarter. Wedmont Private Capital now owns 12,092 shares of the healthcare product maker’s stock worth $1,359,000 after buying an additional 2,458 shares during the last quarter. Institutional investors and hedge funds own 73.70% of the company’s stock.

Insider Activity at Abbott Laboratories

In related news, EVP Daniel Gesua Sive Salvadori sold 963 shares of the company’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $118.50, for a total transaction of $114,115.50. Following the transaction, the executive vice president now directly owns 125,697 shares of the company’s stock, valued at $14,895,094.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, EVP Andrea F. Wainer sold 12,500 shares of the company’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $120.00, for a total transaction of $1,500,000.00. Following the completion of the sale, the executive vice president now owns 78,704 shares in the company, valued at approximately $9,444,480. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Daniel Gesua Sive Salvadori sold 963 shares of the company’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $118.50, for a total value of $114,115.50. Following the sale, the executive vice president now owns 125,697 shares of the company’s stock, valued at approximately $14,895,094.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 56,435 shares of company stock valued at $6,451,298. Company insiders own 1.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on ABT shares. Wells Fargo & Company raised their price target on Abbott Laboratories from $116.00 to $121.00 and gave the stock an “overweight” rating in a report on Wednesday, December 13th. Royal Bank of Canada restated an “outperform” rating and set a $128.00 price objective on shares of Abbott Laboratories in a research report on Wednesday, February 14th. Raymond James boosted their price objective on Abbott Laboratories from $124.00 to $127.00 and gave the company an “outperform” rating in a research report on Thursday, January 25th. Citigroup boosted their price objective on Abbott Laboratories from $123.00 to $126.00 and gave the company a “buy” rating in a research report on Thursday, January 25th. Finally, Barclays boosted their price target on Abbott Laboratories from $133.00 to $141.00 and gave the stock an “overweight” rating in a research report on Friday, January 26th. Four analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average target price of $120.00.

View Our Latest Report on ABT

Abbott Laboratories Stock Down 2.8 %

Shares of Abbott Laboratories stock opened at $115.49 on Friday. The stock’s fifty day moving average is $115.42 and its 200-day moving average is $105.88. The firm has a market capitalization of $200.40 billion, a PE ratio of 35.43, a price-to-earnings-growth ratio of 2.89 and a beta of 0.75. The company has a quick ratio of 1.16, a current ratio of 1.64 and a debt-to-equity ratio of 0.35. Abbott Laboratories has a 12-month low of $89.67 and a 12-month high of $121.64.

Abbott Laboratories (NYSE:ABTGet Free Report) last posted its quarterly earnings results on Wednesday, January 24th. The healthcare product maker reported $1.19 earnings per share for the quarter, meeting the consensus estimate of $1.19. The firm had revenue of $10.24 billion for the quarter, compared to analyst estimates of $10.19 billion. Abbott Laboratories had a return on equity of 20.65% and a net margin of 14.27%. Abbott Laboratories’s quarterly revenue was up 1.5% on a year-over-year basis. During the same period in the previous year, the firm earned $1.03 earnings per share. Equities analysts anticipate that Abbott Laboratories will post 4.62 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 15th. Investors of record on Monday, April 15th will be given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 1.90%. The ex-dividend date is Friday, April 12th. Abbott Laboratories’s payout ratio is 67.48%.

About Abbott Laboratories

(Free Report)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Read More

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABTFree Report).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.